Genecast

Genecast

Private
WuxiHealthcare & Life Scienceshttp://www.genecast.com.cn/

Last Round

Series E

Oct 26, 2020

Est. Valuation

$779.3M

Total Funding Raised

$243.5M

Momentum Score

25 /100

Company Overview

Genecast is a biotechnology company that develops solutions for non-invasive diagnosis and monitoring of cancer.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, Biotech Equipment, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales, Data as a Service

AI Layer

Application

Keywords

NGSnext-generation sequencingmolecular diagnosticslaboratory-developed testLDTliquid biopsyprecision oncologyMRDmolecular residual diseasein-vitro diagnosticsIVDearly cancer detectioncompanion diagnosticsmulti-omics testinggene sequencerbiomarker discoverylab automation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Genecast Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Genecast Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series EOct 26, 2020
Series DOct 30, 2019
Series CFeb 11, 2018
Series BFeb 9, 2017

Key People

Founding team and executive leadership

杜波

CEO

Executive Team

Genecast Investors

Notable investors and investment history

InvestorRounds
Loyal Valley CapitalSeries C
GL VenturesSeries E
Taikang Asset ManagementSeries E
MPCiSeries E, Series D, Series C
China Structural Reform FundSeries E

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2025

    Developing real-time adaptive care for cancer patients with Invitrocue.

  • Jun 17, 2025

    Partnered with Invitrocue for personalized cancer care.

Genecast Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Genecast Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Genecast's valuation, stock price, and market status.

Firmographic Details

HeadquartersWuxi
Employee Range25
Year Founded2014
Last FundingOct 26, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.